Back to News
Market Impact: 0.2
CAPR Investors Have Opportunity to Lead Capricor Therapeutics, Inc. Securities Fraud Lawsuit with SBS Law
Source: PR Newswire
Legal & LitigationHealthcare & Biotech
Schall, Brown & Schwartz LLP reminded investors of a securities class-action lawsuit against Capricor Therapeutics (NASDAQ: CAPR), alleging violations of Sections 10(b) and 20(a) of U.S. securities laws. The notice signals legal risk for Capricor, though the provided article excerpt includes no details on alleged damages, class period, or financial impact.
AllMind Terminal
AI-powered research, real-time alerts, and portfolio analytics for institutional investors.
Request TrialMarket Sentiment
Overall Sentiment
mildly negative
Sentiment Score
-0.20
Ticker Sentiment
CAPR-0.85
More News
- U.S. regulators rush to write crypto rulebook after Clarity Act stalls in Senate
- Meta’s Muse AI is exploding in popularity—and already drawing heated backlash from another tech giant
- NYC Mayor Mamdani reaches record DoorDash settlement for underpaid workers
- Paramount Settlement Triggers WBD Breakout. How It Compares To Past Media Mergers.
- DoorDash will pay $131.5 million for missing and miscalculated NYC delivery worker wages
- Trump admin says it will save $2.2 billion by kicking off 760,000 Affordable Care Act enrollees over fraud claims
From AllMind Research
- Anthropic IPO Preview: Valuation, Timing, and What to Watch
- Shein After the IPO: Venue, Valuation, and What Must Be Proved
- What AI Research Tools Should a Small Hedge Fund Buy First?
- AI Portfolio Monitoring: Build an Alert Policy Analysts Can Audit
- The Great Divergence: North American Banking at the Crossroads of Monetary Policy and Agentic AI (Q4 2025 Bank Earnings)